A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Using Clarithromycin

Gastritis Clinical Trial

Official title:

A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Based on Accurate Susceptibility Testing of Clarithromycin

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02923856
• Other study ID #: SanmenPH
• Status: Recruiting
• Phase: N/A
• Start date: January 2017
• Est. completion date: December 2019

Study information

• Verified date: August 2018
• Source: Sanmen People's Hospital
• Contact: zhang hong Li, doctor
• Email: smyylhz[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

As the resistant rate of the Helicobacter pylori to some common antibiotics was rising，the eradication rate of the Helicobacter pylori with the standard triple therapy failed to exceed 70% in China，and had to drop out of the first-line treatment recommendations. However, with the increase of treatment time, patients burden, adverse reactions of antibiotics or proton pump inhibitor (PPI) will also increase. Resistance to clarithromycin is the major cause of the failure to eradicate Helicobacter pylori. But, in terms of population, there are still more than 70% of the patients with clarithromycin sensitive. Under the guidance with susceptibility test，7-day standard triple therapy could be used. In this study, investigators will select the patients with infection of H. pylori and with clarithromycin sensitive. Eradication of Helicobacter pylori with triple therapy based on accurate susceptibility testing of clarithromycin will be studied. The treatment time will be assigned into 7 days,10 days and 14 days groups. Then, investigators will perform a sequencing for failed treatment patients in groups, such as drug resistance gene mutation, phenotype and genotype. Finally, investigators will compare the differences between the patients with triple therapy and traditional quadruple therapy.The incidence of adverse effects in the eradicate treatment will reduce at least 10% and avoid patients' unnecessary economic losses at least 400RMB per person.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 672
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age 18~70 years old, male or female, the first eradication therapy of H. pylori infection patients.

2. Symptoms of abdominal pain, bloating, acid efflux, belching, nausea, vomiting, heartburn, chest pain, vomiting, melena, etc.

3. Unused antibiotics, bismuth, H2 receptor antagonists or PPI by nearly 4 weeks

4. 13C-labelled urea breath test positive.

5. Agreed to Helicobacter pylori culture and sensitivity testing taken by endoscopy gastric biopsy specimens,and the result of culture was positive.

6. Agreed to Helicobacter pylori eradication therapy and cooperate with the eradication efficacy follow-up survey.

Exclusion Criteria:

1. Severe heart, liver, kidney dysfunction.

2. Pregnant or lactating women.

3. Complications of bleeding, perforation, pyloric obstruction, cancer.

4. Within 3 months before with the drugs involved in other drugs research.

5. Esophageal,gastrointestinal surgery history.

6. Patients can not properly express their complaints,such as psychosis, severe neurosis.

7. Taking NSIAD or alcohol abusers.

8. Allergic to amoxicillin or clarithromycin tested by susceptibility testing.

Related Conditions & MeSH terms

• Gastritis

Intervention

Device:
• The results of clarithromycin susceptibility test of H. pylori isolates
According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
• Computer generated random number, randomly assigned into groups
The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
• The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups
The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.

Locations

Country	Name	City	State
China	Sanmen People's hospital	Taizhou	Zhejiang

Sponsors (8)

Lead Sponsor	Collaborator
Sanmen People's Hospital	Centers for Disease Control and Prevention, China, Taizhou Central Hospital, The First Affiliated Hospital with Nanjing Medical University, The first people Hospital of Wenling, The first people Hospital of Yongkang, Wenzhou Central Hospital, Zhiyuan Medical Inspection Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Impact of mixed infection and CYP2C19 genotype on eradication rate for Helicobacter pylori with triple therapy using clarithromycin.	Investigators will perform a sequencing for failed treatment patients in groups, such as drug resistance gene mutation,and CYP2C19 genotype. Evaluating the impact of mixed infection and CYP2C19 genotype on eradication rate for Helicobacter pylori with triple therapy.	3 years
Primary	The accurate determination of clarithromycin susceptibility.	Assess bacterial susceptibility to antibiotics using the agar diffusion method. The Resistance point of clarithromycin was divided into 0.125µg/ml,0.25µg/ml,0.5µg/ml and 1µg/ml.Test clarithromycin resistance of Helicobacter pylori for patients.	2 years
Primary	Establish individualized precision triple therapy based on minimal inhibitory concentration.	Based on the clarithromycin accurate susceptibility,pinpoint different courses of triple treatment therapy targeted to different people based on minimal inhibitory concentration of clarithromycin.	2.5 years
Secondary	The incidence of adverse effects	Drugs targeted, it could reduce the intake of antibiotics for patients.The incidence of adverse effects in the eradicate treatment will reduce. Avoid patients' unnecessary economic losses.	3 years